Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) EBITDA: 2009-2025

Historic EBITDA for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Sep 2025 value amounting to -$2.0 million.

  • Cumberland Pharmaceuticals' EBITDA fell 15.98% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.3 million, marking a year-over-year increase of 69.70%. This contributed to the annual value of -$6.4 million for FY2024, which is 32.68% up from last year.
  • Cumberland Pharmaceuticals' EBITDA amounted to -$2.0 million in Q3 2025, which was down 162.92% from -$747,478 recorded in Q2 2025.
  • Cumberland Pharmaceuticals' 5-year EBITDA high stood at $1.3 million for Q1 2025, and its period low was -$6.2 million during Q4 2023.
  • For the 3-year period, Cumberland Pharmaceuticals' EBITDA averaged around -$1.6 million, with its median value being -$1.7 million (2024).
  • As far as peak fluctuations go, Cumberland Pharmaceuticals' EBITDA crashed by 4,591.40% in 2024, and later surged by 169.12% in 2025.
  • Over the past 5 years, Cumberland Pharmaceuticals' EBITDA (Quarterly) stood at -$4.4 million in 2021, then surged by 47.68% to -$2.3 million in 2022, then plummeted by 171.28% to -$6.2 million in 2023, then skyrocketed by 70.19% to -$1.8 million in 2024, then dropped by 15.98% to -$2.0 million in 2025.
  • Its EBITDA stands at -$2.0 million for Q3 2025, versus -$747,478 for Q2 2025 and $1.3 million for Q1 2025.